Praxis Precision Medicines Aims for Two U.S. Drug Launches by 2027

Event summary

  • FDA accepted NDAs for ulixacaltamide (Essential Tremor) and relutrigine (DEEs) with PDUFA target dates of January 29, 2027, and September 27, 2026, respectively.
  • EMBRAVE Part A study showed elsunersen achieved a 77% placebo-adjusted reduction in monthly seizures in SCN2A-DEE patients.
  • Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026.
  • Cash and investments of approximately $1.4 billion as of March 31, 2026, maintains runway into 2028.

The big picture

Praxis Precision Medicines is positioning itself for a pivotal period with two potential U.S. drug launches within the next eight months. The company's focus on precision neuroscience and its robust financial position underscore its strategic shift towards commercializing therapies for CNS disorders. The acceptance of NDAs for ulixacaltamide and relutrigine highlights the FDA's recognition of the company's innovative approach to treating movement disorders and developmental epilepsies.

What we're watching

Regulatory Approval
Whether the FDA will approve ulixacaltamide and relutrigine by their respective PDUFA target dates.
Clinical Trial Results
The impact of topline results from the POWER1 study of vormatrigine in Q2 2026 on Praxis' strategic positioning.
Financial Runway
How Praxis will allocate its $1.4 billion cash position to support upcoming launches and R&D initiatives.

Related topics

Drug Development